 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
|
|
The purpose of Cancer News is to provide summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world.
Original news summaries from peer-reviewed journals and
oncology meetings are provided daily.
 |
 News by Cancer Type |
 |
|
| We have categorized our cancer news articles by disease type.
Please select a topic from the drop down list below for more information on
that topic.
|
 |
|
|
 |
|
 |
| Latest Cancer News |
|
|
New Velcade®-melphalan Transplant Regimen for Multiple Myeloma (11/20/2009)
Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.
Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient (11/20/2009)
Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.
Prospective Study Confirms that MRI Detects More Breast Cancers in High-risk Women (11/20/2009)
Researchers from the University of Pennsylvania have reported that magnetic resonance imaging (MRI) is superior to digital mammography or ultrasound for the detection of breast cancer in high-risk women. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on November 2, 2009.
Patterns of Use of Erythropoiesis-stimulating Agents in Medicare Population Reported (11/19/2009)
Researchers from Columbia Medical Center have reported that by 2002, 45.9% of Medicare recipients with common cancers were treated with erythropoiesis-stimulating agents (ESAs) such a Procrit® (epoetin alfa) and Aranesp® (darbepoietin). The details of this study appeared in an early online publication in the Journal of the National Cancer Institute on November 10, 2009.
The Incidence of Smoking-related Bladder Cancer May Be Increasing (11/19/2009)
Researchers from the National Cancer Institute and Dartmouth Medical School have reported that the risk of developing smoking-related bladder cancer has increased in New Hampshire over the risk observed in the 1990s. The details of this study appeared in the November 18, 2009 issue of the Journal of the National Cancer Institute.
Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease (11/19/2009)
Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.
Intravesical Taxotere® Maintenance Therapy May Improve Treatment of Superficial Bladder Cancer Refractory to BCG (11/18/2009)
Researchers from Columbia University have reported that induction and maintenance therapy with intravesical Taxotere® (docetaxel) is well tolerated and effective for treatment of patients with non-muscle-invasive bladder cancer who are refractory to Bacilli Calmette-Guerin (BCG) therapy. The details of this study were reported in the October 2009 issue of British Journal of Urology International.
Physical Activity May Reduce Risk of Developing Prostate Cancer (11/18/2009)
Researchers from U.S. and European medical centers have reported that not sitting during work, occupational activity, walking, and biking can reduce the risk of developing prostate cancer. The details of this study were published early online on October 27, 2009 in the British Journal of Cancer.
New U.S. Preventive Services Task Force Recommendations on Breast Cancer Screening (11/17/2009)
The U.S. Preventive Services Task Force (USPSTF) has released new guidelines for breast cancer screening that increase the interval between screenings for most women. The details of these new guidelines were published in the November 17, 2009 issue of the Annals of Internal Medicine and received prominent first page review in the November 17, 2009 issue of the New York Times.
Regimen of Radiotherapy, Temodar®, Avastin®, and Camptosar® Effective for Glioblastoma (11/17/2009)
Researchers from Duke University have reported that a regimen of radiotherapy (RT), Temodar® (temozolomide), and Avastin® (bevacizumab) followed by Camptosar® (irinotecan), Temodar, and Avastin after RT was well tolerated and effective for treating patients with newly diagnosed glioblastoma. The details of this Phase II study were presented at the 2009 meeting of the American Society of Radiation Therapy and Oncology (ASTRO) in the first week of November.
Elderly Patients with Bulky NHL Who Achieve a PR to Chemotherapy May Benefit from Local Radiotherapy (11/17/2009)
Researchers from Germany have reported that elderly patients with aggressive non-Hodgkin’s lymphoma (NHL) with bulky disease who achieve a partial response (PR) after chemotherapy may benefit from local radiotherapy. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.
Lyrica® Decreases Hot Flashes in Women with Breast Cancer (11/17/2009)
Researchers from the Mayo Clinic have reported that Lyrica® (pregabalin, [S]-3-[aminomethyl]-5-methylhexanoic acid) is effective for the treatment of hot flashes in women with breast cancer. The details of this study appeared in an early online publication on November 9, 2009 in the Journal of Clinical Oncology.
Pertuzumab plus Gemzar® Active in Platinum-resistant Ovarian Cancer (11/16/2009)
Researchers involved in an international randomized trial have reported that pertuzumab may add to the activity of Gemzar® (gemcitabine) for the treatment of platinum-resistant ovarian cancer. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on November 9, 2009.
Presence of Rash Associated with Improved Survival in Patients Receiving Adjuvant Erbitux® for Locally Advanced Head and Neck Cancer (11/16/2009)
A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study were published early online in the Lancet Oncology on November 7, 2009.
Persistent Pain Common After Breast Cancer Surgery (11/16/2009)
Researchers from Denmark have reported that pain and sensory disturbances persist for two to three years after breast cancer surgery. The details of this study were published in the November 11, 2009 issue of the Journal of the American Medical Association.
High-dose Mixed Proton and Photon Radiotherapy May Improve Treatment of Prostate Cancer (11/13/2009)
Researchers affiliated with the Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09 study have reported that mixed proton and photon radiotherapy improves outcomes of patients with low- and intermediate-risk prostate cancer. The details of this randomized trial were presented at the 2009 meeting of the American Society of Radiation Therapy and Oncology (ASTRO) in the first week of November.
Early Morning Colonoscopies Detect More Polyps (11/13/2009)
Researchers affiliated with the Veterans Administration of greater Los Angeles have reported that a greater number of polyps was detected among patients seen early in the morning than among patients seen later in the day. The reasons for this are uncertain, but it’s possible that the lower rate of polyp detection later in the day is the result of provider fatigue or less complete bowel preparation. These results were published in November, 2009 issue of Clinical Gastroenterology and Hepatology.
Primary Care Physicians May Be Ordering More Pap Smears Than Necessary (11/13/2009)
Researchers from the National Institutes of Health have reported that primary care physicians overuse Pap smear testing and are not following current recommendations. The details of this study appeared in the November 3, 2009 issue of the Annals of Internal Medicine.
Excess Body Weight Linked with More Than 100,000 New Cancer Diagnoses Each Year in U.S. (11/12/2009)
According to estimates from the American Institute for Cancer Research (AICR), excess body weight may be responsible for more than 100,000 new cancer diagnoses each year in the United States.
Israeli Jewish Holocaust Survivors May Have Increased Risk of Cancer (11/12/2009)
Researchers from Israel have reported that the incidence of all cancers, and especially breast and colorectal cancers, is higher among Israeli Jews who were potentially exposed to the Holocaust compared with those who were not. The details of this study were published in the November 4, 2009 issue of the Journal of the National Cancer Institute.
Adjuvant Radiotherapy Improves Local Control in High-risk Melanoma Patients (11/12/2009)
Researchers affiliated with the Intergroup Randomized Trial (TROG 01.01/ANZMTG 01.02) have reported that adjuvant radiotherapy (RT) improves regional control for patients with high-risk melanoma without a statistically significant effect on survival. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).
Carbogen and Nicotinamide Improves Survival of Patients with Advanced Bladder Cancer Receiving Radiotherapy (11/11/2009)
Researchers from the UK have reported that patients with locally advanced bladder cancer treated with concomitant carbogen, nicotinamide, and radical accelerated radiotherapy have a 13% improved three-year survival compared with patients treated with radiotherapy alone. The details of this Phase III randomized trial were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.
H-R3 (Nimotuzumab) Enhances Radiation and Chemotherapy Responses in Advanced Head and Neck Cancer (11/11/2009)
Researchers from India have reported that the addition of nimotuzumab to radiation therapy or radiation therapy plus chemotherapy increases long-term loco-regional control and survival in patients with advanced head and neck cancer. The details of this Phase IIB study were presented at the 2009 meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO).
Adjuvant Erbitux® May Improve Survival of High-risk Resected Head and Neck Cancer (11/11/2009)
Researchers affiliated with RTOG 0234 have reported that the addition of Erbitux® (cetuximab) may improve outcomes of patients with high-risk resected head and neck cancer receiving chemoradiotherapy. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology in the first week of November.
Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery (11/10/2009)
Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.
Autologous Stem Cell Transplant with Lentiviral (HIV) Vector Successful in Two Patients with Adrenoleukodystrophy (11/10/2009)
Researchers from France have reported the successful gene transfer, using a lentiviral vector, in two patients with X-linked adrenoleukodystrophy (ALD). The details of this study appeared in the November 6, 2009 issue of Science.
Erbitux® Improves Survival of Patients with Unresectable Head and Neck Cancer Receiving Radiation Therapy and Platinol® (11/10/2009)
Researchers affiliated with ECOG 3303 have reported that the addition of Erbitux® (cetuximab) to concurrent Platinol® (cisplatin) and radiotherapy improves progression-free survival (PFS) and overall survival (OS) in patients with unresectable head and neck cancer who had not been previously treated. The details of this Phase II study were presented at the 2009 meeting of the Association for Therapeutic Radiology and Oncology in the first week of November.
Gemzar® Effective for Peripheral T-cell Lymphomas and Mycosis Fungoides (11/9/2009)
Researchers from Italy have reported that Gemzar® (gemcitabine) is effective single-agent therapy for previously treated patients with peripheral T-cell lymphoma (PTCL) and mycosis fungoides (MF). The details of this study appeared in an early online publication in the Annals of Oncology on November 3, 2009.
Rituxan®-Fludara® Highly Effective for Extranodal MALT B-cell Lymphomas (11/9/2009)
Researchers from Spain have reported that Rituxan® (rituximab) and Fludara® (fludarabine) produces complete remissions in 90% of newly diagnosed patients with extranodal marginal-zone lymphomas of the mucosal-associated lymphoid tissue (MALT) type. The details of this study were published in the November 15, 2009 issue of Cancer.
Oncophage® Cancer Vaccine Shows Promise in Recurrent Glioblastoma (11/9/2009)
Researchers from the Brain Tumor Research Center at the University of California, San Francisco, have reported that Oncophage® (vitespen), a cancer vaccine, may improve survival of patients with recurrent or progressive high-grade glioblastoma. The details of this Phase II clinical trial were presented at the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons (AANS)/CNS section on tumors on October 24.
Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia (11/6/2009)
Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.
Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence (11/6/2009)
Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.
Alcohol May Reduce Risk of Thyroid Cancer (11/6/2009)
Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Continuous Daily Sutent® Palliative in Patients with Relapsed or Refractory Advanced NSCLC (11/5/2009)
Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent® (sunitinib) was associated with a 25% disease control rate in patients with previously treated advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Dose-dense Chemotherapy for Disseminated Thymoma Reported (11/5/2009)
Researchers from Japan have reported that dose-dense chemotherapy is effective for the treatment of patients with Stage IV thymoma. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Childhood Cancer Survivors at Risk for Thyroid Cancer (11/5/2009)
Researchers from the UK have reported that survivors of childhood cancer are 18 times more likely to develop thyroid cancer than the general population. The details of this study appeared in the November 15, 2009 issue of the International Journal of Cancer.
Rapamune™ May Improve Responses to Gleevec® in Patients with Chordoma (11/4/2009)
Researchers from Italy have reported that the addition of Rapamune® (sirolimus, rapamycin) to Gleevec® (imatinib) may improve disease control in patients with chordoma resistant to Gleevec. The details of this study appeared in the November 2009 issue of the Annals of Oncology.
Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell Carcinoma Receiving Nexavar® (11/4/2009)
Researchers from the M. D. Anderson Cancer Center have reported that the addition of low-dose interferon-alfa (IFN) to Nexavar® (sorafenib) did not improve survivals of patients with advanced renal cell carcinoma (RCC). The details of this study were published early online in Cancer on October 27. 2009.
Anticonvulsants May Improve Survival of Patients with Glioblastoma (11/4/2009)
Researchers from the Mayo Clinic have reported that patients with glioblastoma who are receiving enzyme-inducing anticonvulsant (EIAC) drugs may have improved outcomes compared with similar patients with glioblastoma not taking such drugs. The details of this study appeared in the October 13, 2009 issue of Neurology.
Smoking Cessation Leads to Reduction in Risk of Head and Neck Cancer (11/3/2009)
Researchers involved in the International Head and Neck Cancer Epidemiology Consortium have reported that smoking cessation for one to four years resulted in a 30% reduction in the risk of head and neck cancer. A benefit of cessation of alcohol drinking, however, was not observed until after 20 years or more. The details of this study appeared in an early online publication in the International Journal of Epidemiology on October 5, 2009.
Risk of Pancreatic Cancer in Families with Lynch Syndrome Defined (11/3/2009)
Researchers from several U.S. medical centers have reported that patients with Lynch syndrome have an 8.6-fold increase in the risk of pancreatic cancer compared with the general population. The details of this study appeared in the October 28, 2009 issue of the Journal of the American Medical Association.
New Analysis Suggests Decreased Mortality from Hormone Replacement Therapy in Younger Postmenopausal Women (11/3/2009)
Researchers from Stanford University, McMaster University, California Institute of Technology, and Cornell University have reported that hormone replacement therapy (HRT) may reduce mortality by 28% in younger postmenopausal women. The details of this study appeared in the November 2009 issue of the American Journal of Medicine.
Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (11/2/2009)
The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab).
Addition of Xeloda® to Gemzar® Improves Outcomes in Pancreatic Cancer (11/2/2009)
Researchers affiliated with the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) have reported that the addition of Xeloda® (capecitabine) to Gemzar® (gemcitabine) improves outcomes of patients with advanced or metastatic pancreatic cancer. The details of this study appeared early online October 26, 2009 in the Journal of Clinical Oncology.
Concurrent Chemoradiotherapy Improves Outcomes of Patients with Advanced Head and Neck Cancer (11/2/2009)
Researchers affiliated with the UK Head and Neck (UKHAN1) trial have reported that concurrent chemoradiotherapy reduces recurrences and death in patients with advanced head and neck cancer. The details of this study appeared in an early online publication in Lancet Oncology on October 28, 2009.
Vaccination for HPV in Females Associated with a Decline in Genital Warts in Females and Males (10/29/2009)
Researchers from Australia have reported a decline in the number of cases of genital warts in women and men since the initiation of quadrivalent vaccination to prevent human papillomavirus (HPV) infection. The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 16, 2009.
Knowledge Deficits Limit Use of HPV Vaccine in Young Women (10/29/2009)
Researchers from Roswell Park Cancer Institute, Upstate Medical University and the State University of New York at Buffalo have reported that knowledge and risk perceptions among college students limits vaccination for human papillomavirus (HPV). The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 19, 2009.
Nexavar® May Reduce Brain Metastases in Patients with Metastatic Renal Cell Carcinoma (10/28/2009)
Researchers from France and Poland have reported that Nexavar® (sorafenib) may reduce the incidence of brain metastases in patients with metastatic renal cell carcinoma (RCC). The details of this study appeared early online on October 22, 2009 in the Annals of Oncology.
HPV Vaccination Not Cost-effective for Women over 30 Years of Age (10/28/2009)
Researchers from the Harvard School of Public Health have reported that human papillomavirus vaccination for prevention of cervical cancer is not cost-effective in women between the ages of 35 and 45 years. The details of this report appeared in the October 20, 2009 issue of the Annals of Internal Medicine.
Long-term Follow-up Validates Effectiveness of Neoadjuvant Chemotherapy for Esophageal Cancer (10/27/2009)
Researchers from the UK have reported that neoadjuvant chemotherapy improves five-year survival from 17.1% to 23.0% in patients with resectable esophageal cancer. The details of this study appeared in the October 20, 2009 issue of the Journal of Clinical Oncology.
Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer (10/27/2009)
Researchers from Spain have reported that neoadjuvant Taxotere® (docetaxel) and androgen deprivation therapy (ADT) was well tolerated and associated with a 6% pathological complete response (pCR) rate and a 6% near pCR rate in men with high-risk prostate cancer. The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
New Oral Agent, Tasquinimod, May Have Activity in Prostate Cancer (10/26/2009)
Researchers from Sweden have reported that tasquinimod, an oral analog of linomide, may have significant activity in men with hormone-refractory prostate cancer (HRPC). The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
Xcytrin® (Motexafin Gadolinium) May Improve Results of Zevalin® for Treatment of Refractory NHL (10/26/2009)
Researchers from the Robert H Lurie Comprehensive Cancer Center have reported that the addition of Xcytrin® to Zevalin® ([90Y] ibritumomab tiuxetan) may improve treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The details of this study appeared early online in Clinical Cancer Research.
CDC Panel Rejects Routine Vaccination of Boys with Gardasil® but Approves use for Preventing Genital Warts (10/26/2009)
On September 9, 2009, a U.S. FDA advisory panel voted for approval of the use of Gardasil® for the prevention of genital warts in males ages nine through 16. The age range was based on safety data for this age group. However, another U.S. FDA advisory panel, on 10/21/2009, voted against the routine use of Gardasil for vaccination of all young boys.
Platinol® and Surgery Optimal Therapy for Standard-risk Hepatoblastoma in Children (10/23/2009)
Researchers affiliated with International Childhood Liver Tumor Strategy Group (SIOPEL) 2 trial have reported that neoadjuvant and adjuvant treatment with Platinol® (cisplatin) alone is as effective as Adriamycin® (doxorubicin) plus Platinol, with less toxicity, in children with standard-risk hepatoblastoma. The details of this study were published in the October 22, 2009 issue of the New England Journal of Medicine.
Addition of Thalomid® to Autologous Stem Cell Transplantation May Improve Outcomes in Patients with Myeloma (10/23/2009)
Researchers from Italy have reported that “the addition of first-line thalidomide to double ASCT [autologous stem cell transplant] improved clinical outcomes” for patients with multiple myeloma. The details of this study appeared in the October 20, 2009 issue of the Journal of Clinical Oncology.
Gemzar® More Effective than Mutamycin® for Recurrent Superficial Bladder Cancer (10/23/2009)
Researchers from Italy have reported that intrabladder treatment with Gemzar® (gemcitabine) is more effective than Mutamycin® (mitomycin C) for the treatment of recurrent bladder cancer. The details of this randomized trial were published early online in the Journal of Clinical Oncology on October 19.
Breast Self-examination Detects New Breast Cancers in High-risk Women (10/22/2009)
Researchers from Duke University have reported that breast self-examination (BSE) is a useful technique for detecting breast cancer in high-risk women. The details of this study were published in the October 2009 issue of the American Journal of Surgery.
Amrubicin® and Paraplatin® Active and Tolerable in Elderly Patients with SCLC (10/22/2009)
Researchers from Japan have reported Amrubicin®, a new synthetic anthracycline, combined with Paraplatin® (carboplatin) resulted in an 89% overall response rate (ORR) in elderly patients with small cell lung cancer (SCLC). The details of this report appeared in an early online publication in the Annals of Oncology on October 13, 2009.
Multimodality Therapy with Hyperthermia Promising for High-risk Bladder Cancer (10/22/2009)
Researchers from Germany have reported that a strategy of transurethral resection followed by chemoradiotherapy with regional deep hyperthermia results in local recurrence-free survival of 85% in patients with high-risk Stage I and II bladder cancer. The details of this study were published early online in Radiotherapy and Oncology on October 19, 2009.
Arsenic Exposure May Be Related to Survival of Patients with Bladder Cancer (10/21/2009)
Researchers from Dartmouth Medical School have reported that patients with bladder cancer with high arsenic exposure had a lower survival rate than patients with bladder cancer without a high arsenic exposure. The details of this study appeared in an early online publication in the World Journal of Urology on October 16, 2009.
Torisel® Active in Relapsed or Refractory Mantle Cell Lymphoma (10/21/2009)
Researchers from Germany have reported that Torisel® (temsirolimus) improves progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL). The details of this Phase III study were published in the August, 2009 issue of the Journal of Clinical Oncology.
Coffee Consumption May Decrease Risk of Developing Uterine Cancer (10/21/2009)
Researchers from the Karolinska Institute in Sweden have reported that coffee consumption may be associated “with decreased risk of endometrial cancer, especially among women with excessive body weight.” The details of this study were published in the November 15, 2009 issue of the International Journal of Cancer.
Understanding Cancer Video Series Documents SABCS 2009 (10/20/2009)
CancerConsultants.com and Women Magazine have partnered to produce compelling and educational video coverage of The San Antonio Breast Cancer Symposium (SABCS) for the ongoing educational video series, Understanding Cancer. The SABCS videos will be podcast and syndicated to cancer centers and clinics nationally as well as www.cancerconsultants.com.
Exercise Improves Fatigue Related to Chemotherapy (10/20/2009)
Researchers from Denmark have reported that multimodal exercise intervention reduced fatigue and “improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing, but not quality of life” in men and women receiving chemotherapy. The details of this study were published October 13, 2009 online in the British Medical Journal.
Breast Tenderness After Hormone Replacement Therapy Associated with Increased Risk of Breast Cancer (10/20/2009)
Researchers affiliated with the Women’s Health Initiative Estrogen + Progesterone Trial have reported that breast tenderness occurring in postmenopausal women after taking hormone replacement therapy (HRT) is associated with an increased risk of developing breast cancer compared with women taking HRT who do not develop breast tenderness. The details of this study appeared in the October 12, 2009 issue of the Archives of Internal Medicine.
Vitamin D Deficiency Common in Breast Cancer (10/19/2009)
Researchers from the University of Rochester have reported that 69% of women with localized breast cancer receiving adjuvant therapy were deficient in vitamin D. Vitamin D deficiency was corrected with high-dose, as opposed to low-dose, vitamin D supplementation. The details of this study were presented at the American Society of Clinical Oncology breast cancer symposium on October 8, 2009 in San Francisco.
HPV Vaccine, Cervarix®, Approved by the U.S. FDA (10/19/2009)
The U.S. Food and Drug Administration has approved Cervarix®, a vaccine against two high-risk types of human papillomavirus (HPV), for prevention of cervical cancer and cervical precancers. This is the second HPV vaccine to be approved in the United States.
Treatment at High-volume Hospitals Improves Survival in Women with Ovarian Cancer (10/19/2009)
Researchers from Finland have reported that low hospital volume is associated with residual tumor in women with ovarian cancer. The details of this study appeared in the November, 2009 issue of Gynecologic Oncology.
Adjuvant Radiotherapy May Improve Survival in Stage III Node-positive Uterine Cancer (10/16/2009)
Researchers from the University of California at San Francisco have reported that adjuvant radiotherapy improves survival of women with stage III node-positive uterine cancer. The details of this study appeared in the November, 2009 issue of Gynecologic Oncology.
Oral S-1 Can Substitute for 5-FU for Treatment of Metastatic Gastric Cancer (10/16/2009)
Researchers from Japan involved in a multicenter clinical trial have reported that oral S-1 is non-inferior to 5-Fluorouracil (5-FU) or Camptosar® (irinotecan) and Platinol® (cisplatin) for treatment of metastatic gastric cancer. The details of this randomized study were published early on-line in Lancet Oncology on October 8, 2009.
Stereotactic Radiosurgery Alone is Preferred Treatment for Patients with One to Three Brain Metastases (10/15/2009)
Researchers from the MD Anderson Cancer Center have reported that patients with one to three brain metastases treated with stereotactic radiosurgery (SRS) plus whole brain radiation therapy (WBRT) have significant neurocognitive losses after treatment, and that treatment with SRS alone is recommended. The details of this randomized study were published early online in Lancet Oncology on October 8, 2009.
Relative Effectiveness of Minimally Invasive Prostatectomy vs Open Prostatectomy Debated (10/15/2009)
Researchers from Harvard University have reported that men undergoing minimally invasive radical prostatectomy (MIRP) have “a shorter hospital stay, fewer respiratory and miscellaneous surgical complications and strictures, and similar postoperative use of additional cancer therapies but experienced more genitourinary complications, incontinence, and erectile dysfunction” than men undergoing conventional open retropubic prostatectomy (RRP). The details of this study appeared in the October 14, 2009 issue of the Journal of the American Association.
Avastin® Alone or with Camptosar® Effective for Recurrent Gliomas (10/14/2009)
Researchers affiliated with a US multicenter randomized trial have reported that Avastin® (bevacizumab) alone or combined with Camptosar® (irinotecan) was effective for the treatment of recurrent high-grade gliomas. The details of this study were published in the October 1, 2009 issue of the Journal of Clinical Oncology.
Young Women with DCIS Have Higher Risk of Recurrence (10/14/2009)
Researchers from Canada have reported that women age 44 or younger with ductal carcinoma in situ (DCIS) of the breast have a higher rate of recurrence than older women following breast-conserving surgery and radiation therapy. These results were presented at the ASCO 2009 Breast Cancer Symposium in San Francisco, October 8-10, 2009.
High-fiber Diet May Decrease Risk of Postmenopausal Breast Cancer (10/13/2009)
Researchers from the National Institutes of Health (NIH) and AARP have reported that high fiber intake may lower the risk of developing postmenopausal breast cancer. The details of this study appeared in the September, 2009 issue of the American Journal of Clinical Nutrition.
Study Questions Whether or Not HPV Vaccination of Boys Is Cost Effective (10/13/2009)
Researchers from Harvard have reported that including boys in a human papillomavirus (HPV) vaccination program may not be cost effective. The details of this study were published online in the British Medical Journal on October 8, 2009.
Large Open-label Expanded Access Study Confirms Effectiveness of Tykerb® and Xeloda® in Metastatic HER2+ Breast Cancer (10/13/2009)
Researchers involved in the LEAP (Lapatinib Expanded Access Program) international trial have reported that Tykerb® (lapatinib) and Xeloda® (capecitabine) is effective and safe for the treatment of patients with HER2-positive (HER2+) over-expressing locally advanced or metastatic breast cancer who had previously failed treatment with an anthracycline, a taxane, and Herceptin® (trastuzumab). The details of this study appeared early online in the Annals of Oncology on October 8, 2009.
Additional Evidence Regarding the Benefit of Regular Mammograms (10/12/2009)
Researchers from the Massachusetts General Hospital have reported that nearly three-quarters of breast cancer deaths occur among the minority off women who do not get regular screening mammograms. The details of this study were presented at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium held October 8-10 in San Francisco.
Tykerb® plus Femara® Improves Quality-adjusted Survival in Women with HER2+ Metastatic Breast Cancer (10/12/2009)
Researchers affiliated with a large Phase III international randomized trial have reported that Tykerb® (lapatinib) and Femara® (letrozole) improves quality-adjusted survival (Q-TWIST) compared with Femara alone in women with metastatic HER2+ breast cancer. The details of this study were presented at the 2009 ASCO Breast Cancer Symposium in San Francisco, October 8-10.
Gleevec® Improves Outcomes of Children and Adolescents with Ph+ ALL (10/12/2009)
Researchers affiliated with Children’s Oncology Group (COG) have reported that the addition of long-term daily Gleevec® (imatinib mesylate) to high-dose chemotherapy improves event-free survival (EFS) in children and adolescents with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). The details of this study were published online on October 8, 2009.
Cytarabine Improves Results of High-dose Methotrexate in Patients with Primary CNS Lymphoma (10/9/2009)
Researchers involved in a multicenter European-South American study have reported that the addition of high-dose cytarabine to high-dose methotrexate improves the response rate in patients with primary central nervous system lymphoma (PCNSL). The details of this study were published early online on September 20, 2009 in The Lancet.
Smoking May Increase Risk of Breast Cancer (10/9/2009)
Researchers from the Mayo Clinic have reported that women who have smoked 100 or more cigarettes in their life have a significantly increased risk of developing breast cancer. The details of this study were published in the September-October 2009 issue of The Breast Journal.
Radium-223 (Alpharadin®) Effective Palliation for Prostate Cancer Metastatic to Bone (10/9/2009)
Researchers involved in three Phase II European multicenter studies have reported that Alpharadin® (radium-223), an alpha emitter, is effective and well tolerated for the treatment of men with hormone refractory prostate cancer (HRPC) with metastatic bone lesions. The details of these studies were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24 2009.
Nexavar® Confirmed Effective for Patients with Advanced Thyroid Cancer (10/8/2009)
Researchers from the University of Pennsylvania have reported that Nexavar® (sorafenib) appears to have significant activity for patients with differentiated thyroid cancer (DTC). The details of this study were presented as a late-breaking abstract at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Dutasteride Effective in Reducing Risk of Prostate Cancer in High-risk Men (10/8/2009)
Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, have reported that dutasteride, a 5-alpha-reductase inhibitor that inhibits conversion of testosterone into dihydrotestosterone, is effective in reducing the risk of biopsy-proven prostate cancer in men with an elevated prostate specific antigen (PSA) with negative prostate biopsies. The details of this study were reported at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Radiotherapy plus Adjuvant Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Ten-year Results (10/8/2009)
Researchers affiliated with European Organization for Research for the Treatment of Cancer (EORTC) trial 22863 have reported that three years of adjuvant androgen deprivation therapy (ADT) in men with locally advanced prostate cancer receiving radiotherapy improves survival without late cardiovascular toxicity with a 10-year follow-up. The details of this analysis were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Daily Aspirin May Decrease Risk of Colorectal Cancer in Lynch Syndrome (10/7/2009)
Researchers involved in the international multi-institutional study, CAPP2, have reported that the use of daily aspirin may reduce the incidence of colorectal adenomas and cancers in individuals with hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch Syndrome. The details of this study were presented on September 21, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Androgen Deprivation Therapy Increases Risk of Heart Disease in Prostate Cancer (10/7/2009)
Researchers from Sweden have reported that androgen deprivation therapy (ADT) in men with advanced prostate cancer may lead to an increased risk of heart disease. The details of this study were presented September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Twenty-year Results Reported of Autologous Stem Cell Transplants for Hodgkin’s Lymphoma (10/7/2009)
Researchers from the Memorial Sloan-Kettering Cancer Center have reported that accelerated involved field fractionated radiotherapy (IFRT) followed by total lymphoid irradiation (TLI) prior to autologous stem cell transplantation (ASCT) is effected therapy for previously unirradiated patients with refractory or relapsed Hodgkin’s lymphoma (HL). The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Zevalin® Active for Treatment of Extranodal Marginal-zone Lymphoma (10/6/2009)
Researchers from Italy have reported that patients with relapsed or refractory extranodal marginal-zone lymphoma have a high response rate following treatment with Zevalin® (90Yttrium-ibritumomab tiuxetan). The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Folotyn™: First Drug Approved by the U.S. FDA for Treatment of Peripheral T-Cell Lymphoma (10/6/2009)
On September 25, 2009 the U.S. Food and Drug Administration approved Folotyn™ (pralatrexate) for the treatment of peripheral T-cell lymphoma (PTCL). This is the first drug specifically approved for the treatment of PTCL. The basis for this approval was the international PROPEL (Pralatrexate in patients with Relapsed OR refractory PEripheral T-cell Lymphoma) trial. An update of the PROPEL trial was presented at the Joint ECCO 16 -34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
New Proteasome Inhibitor, Carfilzomab, Has Significant Activity in Relapsed Myeloma (10/6/2009)
Researchers affiliated with the Multiple Myeloma Research Consortium (MMRC) have reported that carfilzomab monotherapy is highly active in patients with relapsed myeloma and can be administered safely for at least one year in responding patients. The details of this study were presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Sandostatin LAR Depot Active Against Advanced Neuroendocrine Tumors of the Midgut (10/5/2009)
Researchers from Germany have reported that Sandostatin® LAR Depot (octreotide acetate for injectable suspension) significantly delays time to cancer progression in patients with advanced neuroendocrine tumors of the midgut compared with placebo. The details of this study appeared in the October 1, 2009 issue of the Journal of Clinical Oncology.
Neoadjuvant Chemotherapy with Regional Hyperthermia Improves Outcomes for Soft Tissue Sarcoma (10/5/2009)
Researchers affiliated with EORTC-ESHO Intergroup Trial (NCI-00003052) have reported that neoadjuvant chemotherapy with regional hyperthermia (RHT) improves outcomes of patients with high-risk soft tissue sarcoma (STS) compared with standard neoadjuvant chemotherapy. The results of this randomized study were presented on September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Surgical Resection of Primary Tumor May Improve Survival in Metastatic Breast Cancer (10/5/2009)
Researchers from the Netherlands have reported that women with distant metastatic disease upon diagnosis of breast cancer may benefit from removal of the primary tumor. The results of this study were presented on September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Nurses’ Health Study Helps Define Risk of Colon Cancer up to Age 70 Years (10/2/2009)
Researchers affiliated with the Nurses’ Health Study have reported that women with a high risk factor profile for developing colon cancer can reduce risk by a healthier lifestyle. The details of this study appeared in the October 2009 issue of the American Journal of Epidemiology.
Breast Cancer Mortality Rates Continue to Decline (10/2/2009)
According to a report issued by the American Cancer Society, breast cancer death rates in the United States continue to decline by more than 2% per year. This and other breast cancer statistics were published in Breast Cancer Facts & Figures 2009-2010.
Erbitux® May Improve Treatment of Squamous Cell Carcinoma of the Esophagus (10/2/2009)
Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.
Doxil® and Paraplatin® Superior to Taxol® and Paraplatin for Relapsed Ovarian Cancer (10/1/2009)
Researchers affiliated with the Gynecologic Cancer Intergroup (CCIG) trial CALYPSO have reported that Doxil®, also marketed as Caelyx® and Myocet® (pegylated liposomal doxorubicin) and Paraplatin® (carboplatin) was more effective and better tolerated than Taxol® (paclitaxel) and Paraplatin for partially platinum-sensitive ovarian cancer (patients who relapse between six and 12 months). The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
|
|
|
|
 Member Center |
|
|
 |
Register in our member center today to receive email notification of late breaking cancer news.
Learn More »
|
|
|
|
|
|
|
 Practice Resources |
|
|
 |
Learn how to receive our news headlines on your website.
Learn More »
|
|
|
|
|
|
|
 Links to Information by Cancer Type |
|
|
|
|
|
|
|
|
|
Patient Home
